BASIC AND CLINICAL STUDIES ON CEFDINIR

We studied the antibacterial activity, absorption, excretion and clinical efficacy on cefdinir (CFDN), a new oral cephalosporin, and obtained the following results. 1. Antibacterial activity: the antibacterial activity of CFDN against 25 clinical isolates each of 5 organisms was investigated. CFDN h...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 37; no. Supplement2; pp. 426 - 435
Main Authors MORITA, MASAYUKI, MATSUMOTO, FUMIO, IMAI, TAKEO, KOKUBU, KATSUYA, HOJO, TOSHIO, SAKURAI, IWAO, TAURA, YUJI, TAKAHASHI, TAKAYUKI
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1989
公益社団法人 日本化学療法学会
Subjects
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.37.Supplement2_426

Cover

More Information
Summary:We studied the antibacterial activity, absorption, excretion and clinical efficacy on cefdinir (CFDN), a new oral cephalosporin, and obtained the following results. 1. Antibacterial activity: the antibacterial activity of CFDN against 25 clinical isolates each of 5 organisms was investigated. CFDN had a broad- spectrum activity against Gram-positive and-negative organisms, and the MIC90s against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and methicillin-resistant S. aureus were 6.25, 1.56, 1.56, 1.56 and 50μg/ml, respectively. 2. Absorption and excretion: in adult and elderly subjects, the peak plasma concentrations of CFDN were 1.51 and 1.15μg/ml, respectively, 3-4 hours after a single oral administration of 200mg; the plasma half-lives were 1.76 and 1.90h, and the plasma concentrations at 12 h after dosing were 0.11 and 0.08μg/ml. In elderly subjects administered 100mg of CFDN the plasma concentration was 0.85μg/ml 3h. after administration with a plasma half-life of 1.76 h. The plasma concentration at 12 h after dosing was 0.035μg/ml. The 12-h urinary recovery rate was 16-26%. The peak sputum concentrations ranged from 0.057-0.088μg/ml in 2 patients with bronchial asthma after a single dose of 200mg. 3. Clinical evaluation: CFDN was administered orally at 100 and 200mg 2 or 3 times a day to 24 patients with respiratory tract infections. The clinical response was good in 22 cases and fair and poor in 1 each. A side effect, light headedness, was observed in one case, but no abnormal value was noted.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.37.Supplement2_426